Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | GGPS1 | O95749 | 6/20 | 0.38 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.38 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.37 |
| ▸ | FDPS | P14324 | 9/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.35 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11355071 | 1.00 | TSHR (0.46) | TSHRALDH1A1TDP1THRBGGPS1 | |
| SCHEMBL3148134 | 1.00 | TSHR (0.46) | TSHRALDH1A1TDP1THRBGGPS1 | |
| SCHEMBL3169691 | 0.97 | TSHR (0.48) | TSHRALDH1A1TDP1THRBGGPS1 | |
| SCHEMBL763414 | 0.89 | — | — | |
| SCHEMBL20299935 | 0.81 | TSHR (0.44) | TSHRTHRBGGPS1SMPD1FDPS | |
| SCHEMBL9576868 | 0.81 | TSHR (0.44) | TSHRTHRBGGPS1SMPD1FDPS | |
| SCHEMBL7208110 | 0.81 | TSHR (0.44) | TSHRTHRBGGPS1SMPD1FDPS | |
| SCHEMBL20299931 | 0.81 | TSHR (0.44) | TSHRTHRBGGPS1SMPD1FDPS | |
| SCHEMBL6658765 | 0.81 | TSHR (0.44) | TSHRTHRBGGPS1SMPD1FDPS | |
| SCHEMBL11699499 | 0.81 | TSHR (0.44) | TSHRTHRBGGPS1SMPD1FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104250212-A | Method for preparing highly pure danshinolic acid A | WUXI TARGET DRUG RES CO LTD | 2014-12-31 | — | — | CN | claimed |
| CN-104788485-B | The method for preparing antiviral agent | 百时美－施贵宝爱尔兰控股公司 | 2017-10-03 | — | — | CN | disclosed |
| US-9393200-B2 | Lipopolyamines of spermine type for construction of liposomal transfection systems | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) | 2016-07-19 | — | — | US | disclosed |
| CN-101918358-B | Novel vitamin D receptor activators and methods of manufacture | ABBVIE (US) | 2015-10-14 | — | — | CN | disclosed |
| CN-104788485-A | Process for preparing antiviral agent | BRISTOL MYERS SQUIBB CO | 2015-07-22 | — | — | CN | disclosed |
| CN-102675355-B | Process for preparing the antiviral agent [1S-(1alpha,3 alpha,4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | BRISTOL MYERS SQUIBB CO | 2015-05-06 | — | — | CN | disclosed |
| CN-104250212-A | Method for preparing highly pure danshinolic acid A | WUXI TARGET DRUG RES CO LTD | 2014-12-31 | — | — | CN | disclosed |
| CN-104211626-A | NEW VITAMIN D RECEPTOR ACTIVATORS AND METHODS OF MAKING | ABBVIE INC | 2014-12-17 | — | — | CN | disclosed |
| US-8377913-B2 | Vitamin D receptor activators and methods of making | ABBVIE INC. (US) | 2013-02-19 | — | — | US | disclosed |
| CN-101899063-B | Process for preparing the antiviral agent [1S-(1alpha,3 alpha,4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | BRISTOL MYERS SQUIBB CO | 2012-12-12 | — | — | CN | disclosed |
| US-20060106215-A1 | Process for preparing the antiviral agent [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | CHAN YEUNG Y | 2006-05-18 | — | — | US | disclosed |
| US-7034152-B2 | Process for preparing the antiviral agent [1S-(1alpha,3 alpha,4beta )]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-04-25 | — | — | US | disclosed |
| EP-1644384-A2 | PROCESS AND INTERMEDIATES FOR SYNTHESIS ENTECAVIR | Bristol-Myers Squibb Company (US) | 2006-04-12 | — | — | EP | disclosed |
| CN-1747959-A | Process for the preparation of the antiviral agent [ 1S- (1 α, 3 α, 4 β) ] -2-amino-1, 9-dihydro-9- [ 4-hydroxy-3- (hydroxymethyl) -2-methylenecyclopentyl ] -6H-purin-6-one | BRISTOL MYERS SQUIBB CO (US) | 2006-03-15 | — | — | CN | disclosed |
| US-20040192912-A1 | Process for preparing the antiviral agent [1S-(1alpha,3 alpha,4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-30 | — | — | US | disclosed |
| WO-2004052310-A2 | PROCESS AND INTERMEDIATES FOR SYNTHESIS ENTECAVIR | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-06-24 | — | — | WO | disclosed |
| US-6383669-B1 | COMPRISING ZIRCONIUM COMPLEXES WITH A BETA-DIKETONATE AND ALKANOL GROUPS; ELECTRO-CERAMIC DEVICES THEREFROM; USE IN FERRO-ELECTRIC MEMORIES AND INFRA-RED DETECTORS; ZIRCONIUM DIISOPROPOXY BIS(TETRAMETHYLHEPTANEDIOATE) FOR EXAMPLE | THE SECRETARY OF STATE FOR DEFENCE IN HER BRITANNIC MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND (GB) | 2002-05-07 | — | — | US | disclosed |
| US-6011060-A | TREATING A DISEASE MEDIATED BY ACTIVATION OF THE TUMOR NECROSIS FACTOR | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-01-04 | — | — | US | disclosed |
| CN-87106830-A | TERTIARY AMINE COMPOUND | — | 1988-06-29 | — | — | CN | disclosed |
| EP-0259977-A2 | Tertiary amine compounds | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192912-A1 | Process for preparing the antiviral agent [1S-(1alpha,3 alpha,4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | SAMHD1, NUDT1, ENTPD1 | TSHR 4276/4885ALDH1A1 1031/4885TDP1 590/4885 |
| US-20060106215-A1 | Process for preparing the antiviral agent [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | SAMHD1, NUDT1, ENTPD1 | TSHR 4332/4885ALDH1A1 976/4885TDP1 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.